AVL-292
| CAS No. | 1202757-89-8 | Cat. No. | BCP07702 |
| Name | AVL-292 | ||
| Synonyms | LMK-235; LMK235; AVL292; AVL 292; | ||
| Formula | C22H22FN5O3 | M. Wt | 423.44 |
| Description | AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed, refractory B cell malignancies including Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin lymphomas. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Cell Cycle/DNA Damage Epigenetics | ||
| Targets | HDAC BTK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.